Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

0.3900 +0.0928 (+31.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Propanc Biopharma, Inc. - Common Stock

News headline image
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention 
From Propanc Biopharma, Inc.
Via GlobeNewswire
Which stocks are moving after the closing bell on Friday? ↗
Via Chartmill
News headline image
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
A World-First, Fully Synthetic Recombinant Version of PRP 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
The Science, Clinical Promise, & Market Outlook 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Shareholder Update
CEO Highlights Significant Progress Achieved & Outlines Ambitious Plans for 2026 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
Joint Research Team Focusing on Impact of PRP Reversal of EMT Pathways as Central Role 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
Results Underscore PRP Candidacy as a Disruptor of the Tumor Microenvironment 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline
Initial Investment of $1 Million Received from Hexstone Capital LLC Upon Closing 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
Initial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
Initial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
From Propanc Biopharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.